source
- AI monitoring tool could generate up to 82-fold ROI in phase-3 oncology trials, study findsAn analysis by the Tufts Center for the Study of Drug Development found that an artificial-intelligence clinical monitoring agent can produce an estimated 82-fold return on investment in phase-3 on…
- Aardvark Therapeutics abandons phase 3 trials after workforce cuts and FDA holdAardvark Therapeutics announced it is walking away from its recently terminated phase 3 trials, stating there are no plans to resume them as originally designed. The decision follows a reduction i…